Savara, Inc. (SVRA)
5.48
+0.13
(+2.43%)
USD |
NASDAQ |
Sep 02, 16:00
5.48
0.00 (0.00%)
After-Hours: 18:50
Savara Research and Development Expense (TTM) : 86.84M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.84M |
| March 31, 2026 | 85.64M |
| December 31, 2025 | 81.40M |
| September 30, 2025 | 83.80M |
| June 30, 2025 | 83.52M |
| March 31, 2025 | 80.38M |
| December 31, 2024 | 78.03M |
| September 30, 2024 | 67.48M |
| June 30, 2024 | 61.04M |
| March 31, 2024 | 52.33M |
| December 31, 2023 | 44.26M |
| September 30, 2023 | 39.14M |
| June 30, 2023 | 33.43M |
| March 31, 2023 | 30.93M |
| December 31, 2022 | 27.88M |
| September 30, 2022 | 27.87M |
| June 30, 2022 | 26.25M |
| March 31, 2022 | 27.09M |
| December 31, 2021 | 28.99M |
| September 30, 2021 | 31.53M |
| June 30, 2021 | 30.60M |
| March 31, 2021 | 29.43M |
| December 31, 2020 | 35.04M |
| September 30, 2020 | 33.60M |
| June 30, 2020 | 37.58M |
| Date | Value |
|---|---|
| March 31, 2020 | 41.96M |
| December 31, 2019 | 38.78M |
| September 30, 2019 | 39.92M |
| June 30, 2019 | 39.85M |
| March 31, 2019 | 38.65M |
| December 31, 2018 | 37.17M |
| September 30, 2018 | 33.75M |
| June 30, 2018 | 29.21M |
| March 31, 2018 | 24.10M |
| December 31, 2017 | 18.51M |
| September 30, 2017 | 15.57M |
| June 30, 2017 | 12.74M |
| March 31, 2017 | 9.868M |
| December 31, 2016 | 14.80M |
| September 30, 2016 | 18.46M |
| June 30, 2016 | 23.65M |
| March 31, 2016 | 30.10M |
| December 31, 2015 | 28.26M |
| September 30, 2015 | 26.04M |
| June 30, 2015 | 24.11M |
| March 31, 2015 | 21.20M |
| December 31, 2014 | 19.44M |
| September 30, 2014 | 18.02M |
| June 30, 2014 | 15.72M |
| March 31, 2014 | 13.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 5.943B |
| Insmed, Inc. | 860.84M |
| United Therapeutics Corp. | 551.50M |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| SELLAS Life Sciences Group, Inc. | 20.35M |